Medicare's GLP-1 rules just changed twice. Here is the map.

For twenty years Medicare was barred from covering weight-loss drugs. In the space of eight months, a copay pilot and a negotiated price cut redrew that landscape.

The GLP-1 Bridge pilot: what it is

The Bridge program is a short-term CMS demonstration that provides eligible Medicare Part D beneficiaries access to certain GLP-1 medications for weight management at a flat copay of about $50 per month, beginning July 1, 2026. It grew out of the November 2025 agreements between the administration and both manufacturers — Novo Nordisk and Eli Lilly — that traded lower government prices for expanded access channels.

It is a pilot, not a permanent benefit. Eligibility criteria, participating plans and the covered product list are defined by the demonstration's terms, and beneficiaries need to confirm their own plan's participation. The historical significance is hard to overstate: Part D has excluded drugs used for weight loss since the program's creation in 2006, and the Bridge is the first program to route obesity treatment through Part D at scale.

The 2027 negotiated price: $274 for semaglutide

On November 25, 2025, CMS announced negotiated prices for the second cycle of the Medicare Drug Price Negotiation Program, effective January 1, 2027. Semaglutide headlines the list: Ozempic, Wegovy and Rybelsus were negotiated as one active ingredient, landing at $274 per 30-day supply against a list price near $959 — a 71 percent reduction. CMS documents show higher Wegovy doses at $385 per month.

Scale explains the selection: roughly 2.3 million Part D enrollees used semaglutide products in 2024, and Medicare spent over $15 billion on them. Across all 15 negotiated drugs, CMS projects savings of $8.5 to $12 billion per year. Tirzepatide (Mounjaro/Zepbound) was not in this cycle; analysts expect it in a later round, with any negotiated price taking effect in 2028 or 2029.

The confusing part: three different prices at once

Between now and 2027, three price regimes overlap. The November 2025 manufacturer deal set a $245 monthly figure for Ozempic and Wegovy in certain government channels; the negotiated Medicare maximum fair price is $274 from January 2027; and self-pay programs (NovoCare, TrumpRx, GoodRx) advertise $199–$499 depending on drug and dose. These are different prices for different buyers, and none of them is automatically what a beneficiary pays at the counter.

What a beneficiary pays depends on their Part D plan's formulary tier, deductible phase and coinsurance — the negotiated price caps what Medicare pays the manufacturer, and out-of-pocket costs flow from plan design. The $2,000 annual Part D out-of-pocket cap (indexed after 2025) remains the beneficiary's backstop.

Indication still decides everything

Traditional Part D coverage of GLP-1s still runs through non-weight-loss indications: type 2 diabetes (Ozempic, Mounjaro, Rybelsus), established cardiovascular disease risk reduction (Wegovy's SELECT-based indication), and obstructive sleep apnea (Zepbound). If you qualify under one of those, standard Part D coverage plus the 2027 negotiated price is your path, and the Bridge pilot is irrelevant to you.

If your only indication is weight management, the Bridge pilot is currently the only Part D route, and its eligibility rules govern. This split will keep producing situations where two people on the identical drug pay very different amounts — the deciding variable is the diagnosis code, not the medication.

What to do, by situation

If you have diabetes, CVD or diagnosed OSA: confirm your 2026 plan's formulary tier for your specific drug now, and expect the semaglutide line to reprice in January 2027 — plans will update tiers during the fall 2026 open enrollment, which is the moment to compare.

If you want GLP-1 treatment for weight alone: ask your Part D plan whether it participates in the GLP-1 Bridge demonstration and what its eligibility documentation requires. If it does not participate, your realistic 2026 options are manufacturer self-pay channels ($199–$499) or verified compounded programs ($147–$259), with the compounded route carrying its usual non-FDA-approved caveats. Manufacturer copay cards, note, cannot legally be combined with Medicare.

One more moving part deserves attention: the interaction between Medicare's changes and the compounded market. Compounded GLP-1s cannot be billed to Medicare and manufacturer copay cards cannot be combined with it, so for beneficiaries the real 2026–2027 comparison is Bridge-pilot copay versus negotiated Part D price versus cash-pay self-funding. As the negotiated $274 price and the pilot mature, the cash-pay compounded route loses much of the price advantage that drove Medicare-age patients toward it, while carrying regulatory and quality risk that insured brand access does not. For most eligible beneficiaries, the durable answer will be a covered indication plus the 2027 price, with the Bridge pilot bridging exactly the gap its name implies.

Frequently asked questions

Does Medicare now cover Wegovy for weight loss?

Only through the GLP-1 Bridge demonstration beginning July 1, 2026, for eligible beneficiaries in participating plans. Standard Part D coverage still requires a non-weight-loss indication like CVD risk reduction.

Will I pay $274 at the pharmacy in 2027?

Not necessarily. $274 is the negotiated maximum fair price Medicare pays; your cost depends on your plan's tier and coinsurance. It should fall substantially, but check your plan's 2027 documents in the fall 2026 open enrollment.

Is tirzepatide getting a negotiated price too?

Not in this cycle. Mounjaro and Zepbound are widely expected in a subsequent negotiation round, with prices effective 2028 or 2029. Zepbound access in 2026 runs through the Bridge pilot, the OSA indication, or self-pay.

Sources

1. CMS negotiated prices via NPR, Nov 26, 2025
2. BioPharma Dive on the 2027 price list
3. GLP-1 Bridge details via Managed Healthcare Executive
4. CMS Medicare Drug Price Negotiation Program